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Background: Many patients with atrial fibrillation (AF) at high risk for
thromboembolic events are not candidates for long-term oral anticoagulation (OAC).
The left atrial appendage (LAA) is the major site of thrombus formation in non-valvular
AF. We report our initial results for LAA occlusion with the AMPLATZER® Cardiac
Plug (ACP) (St. Jude Medical, Plymouth, MN).
Methods: A multicenter European Post Market Registry was initiated to evaluate the
performance of the ACP device in closure of the LAA. A total of 145 pts with non-
valvular AF underwent ACP implantation contributing to the data of this interim
analysis.
Results: The majority of patients (60%) had a history of permanent AF. Mean age was
73.6 ± 8.9, mean CHADS2 score 2.6 ± 1.3. Prior stroke or TIA was reported by 38%
of patients. The majority underwent the procedure for intolerance of Warfarin; only
3.3% of patients were on active OAC prior to implant. The ACP device was
successfully implanted in 96.5% of patients with no device embolizations during the
implant procedure. Acute device/procedure related Adverse Events (AEs) occurred
within 7 days post procedure in 8 out of 145 patients (5,5%), consisting of 3 serious
pericardial effusions, 3 device embolizations, 1 cardiac perforation, and 1 arteriovenous
fistula. All device embolizations occurred early in the learning curve for each of the
implanters. During follow-up after 7 days post implant we observed 3 cases of
thrombus on the device and 1 case of late device embolization. Root cause analysis of
thrombus formation demonstrated the importance of proper implant technique and
adequate anti-thrombotic regimen.
Conclusion: The ACP device demonstrated excellent implant success and closure rates.
The rate of AEs compares favorably with other devices despite the high risk patients
enrolled in the Registry. The enrollment goal of 200 patients is expected to be achieved
in the fall of 2011 with final results available in 2012.
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Background: Prostanoid therapy improves quality of life and may increase survival
in patients with advanced pulmonary hypertension (PH). Balloon atrial septostomy
(BAS) can palliate or a serve as a bridge to transplantation for patients resistant to
medical therapy. The safety and efficacy of BAS in the era of prostanoid therapy has
not previously been reported.
Methods: All patients had progressive symptoms despite prostanoid therapy at the
time of their first BAS. Eleven patients who underwent a total of 16 septostomies
between 2004-11 were included in this retrospective analysis.
Results: Patients were aged 46.9 years ± 10.5 with 8/11 women. Etiologies included
idiopathic (6), methamphetamine (3), scleroderma (1), and anorexigen (1). Survival at
a mean of 739 days was 73%. No patient died within 24 hours post-procedure. 30-day
and 1-year survival were both 82%. Four4 subjects required repeat BAS due to shunt
closure; 3 subjects were successfully bridged to transplant. 9 of 11 patients had
improvement by one functional class. Hemodynamic and echocardiographic
measurements are presented in Table 2in the table. All non-survivors were male and
had higher baseline serum creatinine, mean right atrial pressure, right ventricular (RV)
end diastolic pressure and left ventricular filling pressures, and lower RV ejection
fraction. Mortality was associated with unchanged post-septostomy cardiac output
despite an increase in LVEDP. Tricuspid annular plane systolic excursion (TAPSE)
and serum BNP were not different between the two groups.
Conclusion: BAS appears to be a promising therapy for select PH patients who have
symptomatic progression despite prostanoid therapy. Survival is comparable to prior
reports of patients undergoing BAS in the pre-prostanoid era.
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Background: Balloon aortic valvuloplasty (BAV) for calcific aortic stenosis has
undergone a renaissance, due to transcatheter aortic valve implantation (TAVI) and its
integral use of BAV. We sought to characterise UK BAV experience in the TAVI era.
Methods: Data from 423 patients who had undergone BAV from March 2003 to April
2010 at 14 centres across the United Kingdom were analysed.
Results: Patients were aged 80.9±8.5 (mean±SD) years; 55.0% were male and the
mean logistic EuroScore was 27.8±16.8%. BAV was performed for palliation (40.8%)
or as a bridge to either TAVI (34.1%) or surgical aortic valve replacement (sAVR)
(12.8%). Procedural success was 98.5%, with a median balloon size of 20mm and
2.4±1.6 inflations used. The peak transaortic gradient fell from 77.8±28.2 to 53.5±19.9
mmHg (p<0.001). Procedural complications were: death (2.4%), blood transfusion of
≥2 units (1.2%), cardiac tamponade (1.0%), stroke (1.0%), vascular surgical repair
(1.0%), coronary embolisation (0.5%), worsening of AR by 2 grades (0.5%) and
permanent pacing (0.2%). Mortality at 30-days was 13.2% and 34.8% at 12 months.
At a mean follow-up of 269.7±275.6 days the adverse events seen were death (39.3%),
TAVI (18.2%), sAVR (7.0%) and repeat BAV (3.2%). Multivariate Cox proportional
hazard analysis demonstrated that survival was adversely effected by an urgent (Hazard
Ratio 1.7; 95% Confidence Interval 1.2-2.4) or emergent presentation (HR 3.7; 95%CI
2.3-6.1), poor left ventricular systolic function (HR 1.5; 95%CI 1.1-2.2) and the
presence of coronary disease (HR 1.5; 95%CI 1.1-2.2). The presence of moderate or
severe calcification was inversely related to time to death (HR 0.4; 95%CI 0.3-0.7).
Kaplan Meier analysis demonstrated that repeat BAV had no statistically significant
effect upon survival compared to no treatment(logrank=0.08) but subsequent TAVI or
sAVR improved survival (logrank<0.001).
Conclusion: BAV offers good immediate efficacy at an acceptable risk of
complications. Medium term freedom from death is poor in the absence of definitive
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